GMAB Quote, Financials, Valuation and Earnings

Ascendis Pharma A/S has a net margin of 39.24% compared to Genmab A/S's net margin of -28.55%. Genmab A/S's return on equity of 28.3% beat Ascendis Pharma A/S's return on equity of -880.05%.

Genmab A/S has a consensus price target of $37.81, signalling upside risk potential of 12.14%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $262.82 which suggests that it could grow by 24.92%. Given that Ascendis Pharma A/S has higher upside potential than Genmab A/S, analysts believe Ascendis Pharma A/S is more attractive than Genmab A/S.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.182%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1B, which are larger than Ascendis Pharma A/S quarterly revenues of $249.6M. Genmab A/S's net income of $399.2M is higher than Ascendis Pharma A/S's net income of -$71.3M. Notably, Genmab A/S's price-to-earnings ratio is 14.32x while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.90x versus 17.80x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion AS has a net margin of 39.24% compared to Genmab A/S's net margin of -64.14%. Genmab A/S's return on equity of 28.3% beat Evaxion AS's return on equity of --.

Genmab A/S has a consensus price target of $37.81, signalling upside risk potential of 12.14%. On the other hand Evaxion AS has an analysts' consensus of $14.19 which suggests that it could grow by 188.36%. Given that Evaxion AS has higher upside potential than Genmab A/S, analysts believe Evaxion AS is more attractive than Genmab A/S.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1B, which are larger than Evaxion AS quarterly revenues of $37.5K. Genmab A/S's net income of $399.2M is higher than Evaxion AS's net income of -$4.9M. Notably, Genmab A/S's price-to-earnings ratio is 14.32x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.90x versus 3.30x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Merus NV has a net margin of 39.24% compared to Genmab A/S's net margin of -786.17%. Genmab A/S's return on equity of 28.3% beat Merus NV's return on equity of -53.47%.

Genmab A/S has a consensus price target of $37.81, signalling upside risk potential of 12.14%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.09%. Given that Genmab A/S has higher upside potential than Merus NV, analysts believe Genmab A/S is more attractive than Merus NV.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1B, which are larger than Merus NV quarterly revenues of $12.2M. Genmab A/S's net income of $399.2M is higher than Merus NV's net income of -$95.5M. Notably, Genmab A/S's price-to-earnings ratio is 14.32x while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.90x versus 121.82x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of 39.24% compared to Genmab A/S's net margin of 26.68%. Genmab A/S's return on equity of 28.3% beat Novo Nordisk A/S's return on equity of 68.76%.

Genmab A/S has a consensus price target of $37.81, signalling upside risk potential of 12.14%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.33 which suggests that it could grow by 1.47%. Given that Genmab A/S has higher upside potential than Novo Nordisk A/S, analysts believe Genmab A/S is more attractive than Novo Nordisk A/S.

Genmab A/S has a beta of 0.902, which suggesting that the stock is 9.809% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.29% to investors and pays a quarterly dividend of $0.58 per share. Genmab A/S pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab A/S quarterly revenues are $1B, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Genmab A/S's net income of $399.2M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Genmab A/S's price-to-earnings ratio is 14.32x while Novo Nordisk A/S's PE ratio is 15.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.90x versus 5.01x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.